FIT for CRC Screening

In Europe, colorectal cancer (CRC) is the most prevalent of all tumours, with 471,000 new cases diagnosed per year and second only to lung cancer in terms of deaths. Yet studies show that it is possible to significantly reduce mortality when one adopts population-based CRC screening programmes.

In 2010, a European Parliament resolution called for the adoption of primary prevention and early diagnosis through screening. Some European member states have already started population-based screening programmes, either on a national or regional scale. Others are still assessing and defining strategies for implementation of CRC screening programs or already in the pilot phase. Population between the ages of 50 and 74 are often eligible and invited to participate in CRC screening programs to detect bowel cancer early on.

Due to its simplicity and proven superior performance, the quantitative faecal immunochemical test, or FIT, is currently considered the best, non-invasive Faecal Occult Blood (FOB) test for Screening.


“The FIT Test has a major advantage as it is quantitative so that no interpretation from the doctor is required. Another benefit is you can perform it in high volume because the throughput is fast: you can easily analyse a few thousand tests per day.” 

W.W.J. Spijker, CEO Screening Organisation in The Netherlands

“With simple lab testing you can help save lives.”

Lizet Bosman-Weijzen, Analyst, Geleen, The Netherlands

FIT tests are gaining ground

Success story from the Netherlands

After lung and breast cancer, colorectal cancer is the third most common cancer worldwide. To accelerate arly detection, European countries are now starting to implement population-based screening programmes with FIT (Faecal Immunochemical Testing).

The Netherlands has led the way for four years.

Read the success story now